Securities Registration: Employee Benefit Plan (s-8)

Large accelerated filer

Accelerated filer

Non-accelerated filer

☐ (Do not check if a smaller reporting company)

Smaller reporting company

Emerging Growth Company

As filed with the Securities and Exchange Commission on March 15, 2018

Registration No. 333-

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

CYMABAY THERAPEUTICS, INC.

(Exact name of Registrant as specified in its charter)

Delaware

94-3103561

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

7999 Gateway Blvd., Suite 130

Newark, CA 94560

(Address of principal executive offices) (Zip code)

CymaBay Therapeutics, Inc. 2013 Equity Incentive Plan

(Full title of the plan)

Sujal Shah

President and Chief Executive Officer

CymaBay Therapeutics, Inc.

7999 Gateway Blvd., Suite 130

Newark, CA 94560

(510) 293-8800

(Name and address of agent for service) (Telephone number, including area code, of agent for service)

Copies to:

Matthew B. Hemington

Cooley LLP

3175 Hanover Street

Palo Alto, California 94304

(650) 843-5000

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☒

CALCULATION OF REGISTRATION FEE



Title of Securities to be Registered	Amount to be Registered (1)	Proposed Maximum Offering Price Per Share(2)	Proposed Maximum Aggregate Offering Price(2)	Amount of Registration Fee
Common Stock, par value $0.0001 per share	2,220,439 shares	$13.525	$30,031,437.48	$3,738.91

(1)

Represents additional shares of the Registrant’s common stock, par value $0.0001 (the “ Common Stock ”) issuable under the Registrant’s 2013 Equity Incentive Plan (the “ Plan ”) by reason of the automatic share increase provision of the Plan. Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the “ Securities Act ”). This Registration Statement shall also cover any additional shares of Common Stock that become issuable under the Plan by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration that increases the number of the Registrant’s outstanding shares of Common Stock.

(2)

Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(h) and Rule 457(c) promulgated under the Securities Act. The offering price per share and the aggregate offering price is based upon $13.525, which is the average of the high and low selling prices of the Registrant’s Common Stock as reported on the Nasdaq Capital Market on March 14, 2018.

EXPLANATORY NOTE

CymaBay Therapeutics, Inc. (the “ Registrant ”) is filing this Registration Statement on Form S-8 for the purpose of registering an additional 2,220,439 shares of its Common Stock, issuable to eligible persons under the CymaBay Therapeutics, Inc. 2013 Equity Incentive Plan (“ 2013 Plan ”), which Common Stock is in addition to the shares of Common Stock previously registered on the following Form S-8s (collectively, the “ Prior Form S-8s ”):

•

the Registrant’s Form S-8 filed on April 11, 2014 (File No. 333-195211);

•

the Registrant’s Form S-8 filed on August 21, 2014 (File No. 333-198289);

•

the Registrant’s Form S-8 filed on March 23, 2015 (File No. 333-202941);

•

the Registrant’s Form S-8 filed on March 29, 2016 (File No. 333-210453); and

•

the Registrant’s Form S-8 filed on March 23, 2017 (File No. 333-216905).

PART II

ITEM 3.

INCORPORATION BY REFERENCE

Pursuant to General Instruction E to Form S-8, the contents of the Prior Form S-8s are incorporated herein by reference and made a part hereof.

The following documents filed by the Registrant with the Securities and Exchange Commission are incorporated by reference into this Registration Statement:

The Registrant’s Annual Report on Form 10-K filed on March 15, 2018, under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (File No. 001-36500).

The Registrant’s Current Reports on Form 8-K filed on January 12, 2018 and January 30, 2018, under the Exchange Act (File No. 001-36500).

The description of the Registrant’s common stock contained in the Registrant’s Form 8-A filed on June 16, 2014, including any amendment or report filed for the purpose of updating such description.

All documents, reports and definitive proxy or information statements filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

ITEM 8.

EXHIBITS


Exhibit Number		Description

4.1 ⁽¹⁾		Amended and Restated Certificate of Incorporation of the Registrant.

4.2 ⁽²⁾		Amended and Restated Bylaws of the Registrant.

4.3 ⁽³⁾		Form of Registration Rights Agreement

4.4 ⁽⁴⁾		Form of 2013 Financing Warrant.

4.5 ⁽⁵⁾		Amendment No. 1 to Registration Rights Agreement.

5.1		Opinion of Cooley LLP.

23.1		Consent of Cooley LLP (included in Exhibit 5.1).

23.2		Consent of Independent Registered Public Accounting Firm.

24.1		Power of Attorney (included on the signature page of this Form S-8).

99.1 ⁽⁶⁾		2013 Equity Incentive Plan

99.2 ⁽⁷⁾		Form of Option Grant Notice and Option Agreement under the 2013 Equity Incentive Plan

99.3 ⁽⁸⁾		Form of Incentive Award Grant Notice under the 2013 Equity Incentive Plan

(1)	Previously filed as Exhibit 3.1 to the Registrant’s Amendment No. 2 to Registration Statement on Form 10/A (File No. 000-55021), filed with the Commission on October 17, 2013, and incorporated by reference herein.

(2)	Previously filed as Exhibit 3.2 to the Registrant’s Amendment No. 2 to Registration Statement on Form 10/A (File No. 000-55021), filed with the Commission on October 17, 2013, and incorporated by reference herein.

(3)	Previously filed as Exhibit 4.2 to the Registrant’s Amendment No. 2 to Registration Statement on Form 10/A (File No. 000-55021), filed with the Commission on October 17, 2013, and incorporated by reference herein.

(4)	Previously filed as Exhibit 4.3 to the Registrant’s Amendment No. 2 to Registration Statement on Form 10/A (File No. 000-55021), filed with the Commission on October 17, 2013, and incorporated by reference herein.

(5)	Previously filed as Exhibit 4.4 to the Registrant’s Annual Report on Form 10-K (File No. 000-55021), filed with the Commission on March 31, 2014, and incorporated by reference herein.

(6)	Previously filed as Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No. 000-55021), filed with the Commission on June 6, 2014, and incorporated by reference herein.

(7)	Previously filed as Exhibit 10.26 to the Registrant’s Amendment No. 2 to Registration Statement on Form 10/A (File No. 000-55021), filed with the Commission on October 17, 2013, and incorporated by reference herein.

(8)	Previously filed as Exhibit 10.22 to the Registrant’s Form 10-K, (File No. 000-55021) filed with the SEC on March 31, 2014.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Newark, State of California, on this 15th day of March, 2018.


C YMA B AY T HERAPEUTICS , I NC .

By:		/s/ Sujal Shah
		Sujal Shah
		President and Chief Executive Officer

POWER OF ATTORNEY

K NOW A LL P ERSONS B Y T HESE P RESENTS , that each person whose signature appears below constitutes and appoints Sujal Shah and Daniel Menold, and each of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.


Name and Signature	Title	Date

/s/ Sujal Shah	President, Chief Executive Officer and Director	March 15, 2018
Sujal Shah	(Principal Executive Officer)

/s/ Daniel Menold	Vice President, Finance	March 15, 2018
Daniel Menold	(Principal Financial and Accounting Officer)

/s/ Robert J. Wills	Director	March 15, 2018
Robert J. Wills, Ph.D.

/s/ Carl Goldfischer	Director	March 15, 2018
Carl Goldfischer, M.D.

/s/ Robert Booth	Director	March 15, 2018
Robert Booth, Ph.D.

/s/ Kurt von Emster	Director	March 15, 2018
Kurt von Emster, CFA

/s/ Caroline Loewy	Director	March 15, 2018
Caroline Loewy

/s/ Evan A. Stein	Director	March 15, 2018
Evan A. Stein, M.D., Ph D.

/s/ Paul F. Truex	Director	March 15, 2018
Paul F. Truex

/s/ Robert J. Weiland	Director	March 15 2018
Robert J. Weiland